Literature DB >> 18219824

Role of uric acid in multiple sclerosis.

S Spitsin1, H Koprowski.   

Abstract

In the past decade, a growing number of evidence has implicated free radicals in a variety of pathophysiological conditions including aging, cancer, and coronary heart disease. Analyses of different aspects of multiple sclerosis (MS) pathology with respect to oxidative damage have also revealed evidence of free radical injury to the central nervous system (CNS), although attempts to protect the CNS using various antioxidants have met with only moderate success. Several recent studies have reported lower levels of uric acid (UA), a major scavenger of reactive nitrogen species, in MS patients, while other studies found no such correlation. Here, we discuss these studies as well as current efforts to manipulate serum UA levels in MS patients.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18219824     DOI: 10.1007/978-3-540-73677-6_13

Source DB:  PubMed          Journal:  Curr Top Microbiol Immunol        ISSN: 0070-217X            Impact factor:   4.291


  7 in total

1.  The protective effects of inosine against chemical hypoxia on cultured rat oligodendrocytes.

Authors:  Quan-Rui Ma; Hao Yang; Xiang-Hui Zhao; Yu-Kai Zhang; An-Hui Yao; Peng Cheng; Ya-Bin Xie; Hai-Kang Zhao; Gong Ju; Fang Kuang
Journal:  Cell Mol Neurobiol       Date:  2011-06-05       Impact factor: 5.046

Review 2.  Adenosine-to-inosine RNA editing.

Authors:  Boris Zinshteyn; Kazuko Nishikura
Journal:  Wiley Interdiscip Rev Syst Biol Med       Date:  2009 Sep-Oct

3.  Characterisation of genome-wide association epistasis signals for serum uric acid in human population isolates.

Authors:  Wenhua Wei; Gibran Hemani; Andrew A Hicks; Veronique Vitart; Claudia Cabrera-Cardenas; Pau Navarro; Jennifer Huffman; Caroline Hayward; Sara A Knott; Igor Rudan; Peter P Pramstaller; Sarah H Wild; James F Wilson; Harry Campbell; Malcolm G Dunlop; Nicholas Hastie; Alan F Wright; Chris S Haley
Journal:  PLoS One       Date:  2011-08-19       Impact factor: 3.240

Review 4.  Failed, Interrupted, or Inconclusive Trials on Neuroprotective and Neuroregenerative Treatment Strategies in Multiple Sclerosis: Update 2015-2020.

Authors:  Niklas Huntemann; Leoni Rolfes; Marc Pawlitzki; Tobias Ruck; Steffen Pfeuffer; Heinz Wiendl; Sven G Meuth
Journal:  Drugs       Date:  2021-06-04       Impact factor: 9.546

Review 5.  Inosine in Neurodegenerative Diseases: From the Bench to the Bedside.

Authors:  Maria Sofia Basile; Placido Bramanti; Emanuela Mazzon
Journal:  Molecules       Date:  2022-07-21       Impact factor: 4.927

6.  Is a hypothetical melanoma-like neuromelanin the underlying factor essential for the aetiopathogenesis and clinical manifestations of multiple sclerosis?

Authors:  Bernd Krone; John M Grange
Journal:  BMC Neurol       Date:  2013-07-18       Impact factor: 2.474

7.  GWAS and transcriptional analysis prioritize ITPR1 and CNTN4 for a serum uric acid 3p26 QTL in Mexican Americans.

Authors:  Geetha Chittoor; Jack W Kent; Marcio Almeida; Sobha Puppala; Vidya S Farook; Shelley A Cole; Karin Haack; Harald H H Göring; Jean W MacCluer; Joanne E Curran; Melanie A Carless; Matthew P Johnson; Eric K Moses; Laura Almasy; Michael C Mahaney; Donna M Lehman; Ravindranath Duggirala; Anthony G Comuzzie; John Blangero; Venkata Saroja Voruganti
Journal:  BMC Genomics       Date:  2016-04-02       Impact factor: 3.969

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.